Hepatitis B virus screening before chemotherapy for lymphoma: a cost-effectiveness analysis
Zurawska U, Hicks LK, Woo G, Bell CM, Krahn M, Chan KK, Feld JJ

Record Status
This is an economic evaluation that meets the criteria for inclusion on NHS EED.

Bibliographic details

DOI
10.1200/JCO.2011.40.7510

Original Paper URL
http://jco.ascopubs.org/content/30/26/3167.abstract

Indexing Status
Subject indexing assigned by NLM

MeSH
Aged; Antibodies, Monoclonal, Murine-Derived /adverse effects; Antineoplastic Combined Chemotherapy Protocols /adverse effects; Cost-Benefit Analysis; Cyclophosphamide /adverse effects; Decision Support Techniques; Doxorubicin /adverse effects; Early Diagnosis; Hepatitis B /diagnosis /economics; Hepatitis B Surface Antigens /analysis; Hepatitis B virus; Humans; Lymphoma, Large B-Cell, Diffuse /drug therapy /economics /virology; Middle Aged; Prednisone /adverse effects; Treatment Outcome; Vincristine /adverse effects; Virus Activation /drug effects

AccessionNumber
22012036943

Date bibliographic record published
04/01/2013